[go: up one dir, main page]

WO2012033983A3 - Candesartan pharmaceutical compositions - Google Patents

Candesartan pharmaceutical compositions Download PDF

Info

Publication number
WO2012033983A3
WO2012033983A3 PCT/US2011/050938 US2011050938W WO2012033983A3 WO 2012033983 A3 WO2012033983 A3 WO 2012033983A3 US 2011050938 W US2011050938 W US 2011050938W WO 2012033983 A3 WO2012033983 A3 WO 2012033983A3
Authority
WO
WIPO (PCT)
Prior art keywords
candesartan
pharmaceutical compositions
formulations
preparing
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/050938
Other languages
French (fr)
Other versions
WO2012033983A2 (en
Inventor
Amarnath Suseendharnath
Venkatesh Madhavacharya Joshi
Sunil Reddy Beeram
Venkateswarlu Vobalaboina
Harshal Prabhakar Bhagwatwar
Manish Chawla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd, Dr Reddys Laboratories Inc filed Critical Dr Reddys Laboratories Ltd
Publication of WO2012033983A2 publication Critical patent/WO2012033983A2/en
Publication of WO2012033983A3 publication Critical patent/WO2012033983A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oral pharmaceutical compositions comprising candesartan or its pharmaceutically acceptable salts, esters, solvates, hydrates, enantiomers, polymorphs, or their mixtures, and processes for preparing the same are described. Also described are pharmaceutical formulations comprising compositions containing candesartan or an ester thereof, processes for preparing the formulations, and methods of use, treatment, and administration involving the formulations.
PCT/US2011/050938 2010-09-09 2011-09-09 Candesartan pharmaceutical compositions Ceased WO2012033983A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2650/CHE/2010 2010-09-09
IN2650CH2010 2010-09-09
US41402710P 2010-11-16 2010-11-16
US61/414,027 2010-11-16

Publications (2)

Publication Number Publication Date
WO2012033983A2 WO2012033983A2 (en) 2012-03-15
WO2012033983A3 true WO2012033983A3 (en) 2012-06-07

Family

ID=45811169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/050938 Ceased WO2012033983A2 (en) 2010-09-09 2011-09-09 Candesartan pharmaceutical compositions

Country Status (1)

Country Link
WO (1) WO2012033983A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115177591A (en) * 2022-07-21 2022-10-14 济南市第三人民医院 Candesartan cilexetil-containing liposome, composition and preparation method of composition
CN115671063B (en) * 2022-08-12 2023-10-13 迪沙药业集团有限公司 Candesartan cilexetil pharmaceutical composition and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174312B1 (en) * 1996-09-05 2001-01-16 Karl Laminger Helical wire
US20080269746A1 (en) * 2007-04-24 2008-10-30 Osteolign, Inc. Conformable intramedullary implant with nestable components
US20090306718A1 (en) * 2001-10-18 2009-12-10 Orthoip, Llc Filament and cap systems and methods for the fixation of bone fractures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174312B1 (en) * 1996-09-05 2001-01-16 Karl Laminger Helical wire
US20090306718A1 (en) * 2001-10-18 2009-12-10 Orthoip, Llc Filament and cap systems and methods for the fixation of bone fractures
US20080269746A1 (en) * 2007-04-24 2008-10-30 Osteolign, Inc. Conformable intramedullary implant with nestable components

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOMET: "OptiLock? Periarticular Plating System For Distal Femoral Fractures", PRE-LAUNCH SURGICAL TECHNIQUE, August 2007 (2007-08-01), Retrieved from the Internet <URL:http://www.biomet.co.uk/resource/2051/Distal%20Femoral%20Surgical%20TechFINAL8.01.07.pdf> [retrieved on 20120210] *

Also Published As

Publication number Publication date
WO2012033983A2 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
EP4289838A3 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP3626253A3 (en) Stable formulations of linaclotide
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009140341A3 (en) Atorvastatin compositions
UA109868C2 (en) N -alkyltriazole compounds asr
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
PL2229938T3 (en) Ezetimibe compositions
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2011089126A3 (en) Novel retigabine composition
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2011097946A8 (en) Oxazolidinone compounds containing ring-fused bicyclic ring, preparation method and use thereof
MX2013007892A (en) Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines.
WO2009060952A1 (en) Novel preparation
WO2011152809A3 (en) Effervescent formulations comprising cephalosporin and clavulanic acid
JO3587B1 (en) Oral dosage forms of bendamustine
WO2011113000A8 (en) Novel ester containing compositions and methods
UA105285C2 (en) Solid pharmaceutical composition comprising ramipril and amlodipine besilate and method for its preparation
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2008004100A9 (en) Therapeutic compounds
WO2012033983A3 (en) Candesartan pharmaceutical compositions
WO2011125006A3 (en) Sultam compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11824161

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11824161

Country of ref document: EP

Kind code of ref document: A2